"there should be 'compensating upside' for the few drugs that do make it to market to ensure investors continue to fund companies’ uncertain R&D efforts" Ok, t

"there should be 'compensating upside' for the few drugs that do make it to market to ensure investors continue to fund companies’ uncertain R&D efforts" Ok, then open your books so we can see why you're pricing the way you are. Obviously, given all the recent attention this has gotten, the industry is not being very transparent about this. Why has no "outsider" been able to connect these dots and why are you (the industry) preventing them from doing so?